MedTrace Logo

Dalteparin in Preventing DVT in Participants With Cancer

NCT00525057 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-01-22

Study results available
· View outcomes & findings →

Summary

This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.

Conditions

  • Bone Sarcoma
  • Femur Fracture
  • Lymphoma
  • Metastatic Neoplasm
  • Pathologic Fracture
  • Plasma Cell Myeloma
  • Soft Tissue Sarcoma

Interventions

DRUG

Dalteparin

Given SC

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Patrick Lin · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-07
Primary Completion
2020-06-19
Completion
2020-06-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525057 on ClinicalTrials.gov